{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:59:20Z","timestamp":1791946760420,"version":"4.3.4"},"reference-count":49,"publisher":"Pharmaceutical Society of Japan","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2023,12,1]]},"DOI":"10.1248\/bpb.b23-00503","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T22:15:45Z","timestamp":1698358545000},"page":"1769-1777","source":"Crossref","is-referenced-by-count":3,"title":["TNF-\u03b1 Mediated the Disruption of Hepatic Tight Junction Expression in Blood\u2013Biliary Barrier of Colitis <i>via<\/i> Downregulating PI3K\/AKT Signaling Pathway"],"prefix":"10.1248","volume":"46","author":[{"given":"Xian-sen","family":"Jiang","sequence":"first","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-le","family":"Fu","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University"},{"name":"College of Pharmacy, Lanzhou University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-xin","family":"Yang","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-yan","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, First Hospital of Lanzhou University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Guillo L, D\u2019Amico F, Serrero M, Angioi K, Loeuille D, Costanzo A, Danese S, Peyrin-Biroulet L. Assessment of extraintestinal manifestations in inflammatory bowel diseases: a systematic review and a proposed guide for clinical trials. United European Gastroenterol. J.<\/i>, 8<\/b>, 1013\u20131030 (2020).","DOI":"10.1177\/2050640620950093"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Barberio B, Massimi D, Cazzagon N, Zingone F, Ford AC, Savarino EV. Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: a systematic review and meta-analysis. Gastroenterology<\/i>, 161<\/b>, 1865\u20131877 (2021).","DOI":"10.1053\/j.gastro.2021.08.032"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Rojas-Feria M, Castro M, Su\u00e1rez E, Ampuero J, Romero-G\u00f3mez M. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J. Gastroenterol.<\/i>, 19<\/b>, 7327\u20137340 (2013).","DOI":"10.3748\/wjg.v19.i42.7327"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Yamamoto-Furusho JK, S\u00e1nchez-Osorio M, Uribe M. Prevalence and factors associated with the presence of abnormal function liver tests in patients with ulcerative colitis. Ann. Hepatol.<\/i>, 9<\/b>, 397\u2013401 (2010).","DOI":"10.1016\/S1665-2681(19)31615-1"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Gaspar R, Branco CC, Macedo G. Liver manifestations and complications in inflammatory bowel disease: a review. World J. Hepatol.<\/i>, 13<\/b>, 1956\u20131967 (2021).","DOI":"10.4254\/wjh.v13.i12.1956"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Roehlen N, Roca Suarez AA, El Saghire H, Saviano A, Schuster C, Lupberger J, Baumert TF. Tight junction proteins and the biology of hepatobiliary disease. Int. J. Mol. Sci.<\/i>, 21<\/b>, 825 (2020).","DOI":"10.3390\/ijms21030825"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Ohtani N, Kawada N. Role of the gut-liver axis in liver inflammation, fibrosis, and cancer: a special focus on the gut microbiota relationship. Hepatol. Commun.<\/i>, 3<\/b>, 456\u2013470 (2019).","DOI":"10.1002\/hep4.1331"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Wiest R, Albillos A, Trauner M, Bajaj JS, Jalan R. Targeting the gut-liver axis in liver disease. J. Hepatol.<\/i>, 67<\/b>, 1084\u20131103 (2017).","DOI":"10.1016\/j.jhep.2017.05.007"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Kojima T, Yamamoto T, Murata M, Chiba H, Kokai Y, Sawada N. Regulation of the blood\u2013biliary barrier: interaction between gap and tight junctions in hepatocytes. Med. Electron Microsc.<\/i>, 36<\/b>, 157\u2013164 (2003).","DOI":"10.1007\/s00795-003-0220-5"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Gissen P, Arias IM. Structural and functional hepatocyte polarity and liver disease. J. Hepatol.<\/i>, 63<\/b>, 1023\u20131037 (2015).","DOI":"10.1016\/j.jhep.2015.06.015"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Fallon MB, Brecher AR, Balda MS, Matter K, Anderson JM. Altered hepatic localization and expression of occludin after common bile duct ligation. Am. J. Physiol.<\/i>, 269<\/b>, C1057\u2013C1062 (1995).","DOI":"10.1152\/ajpcell.1995.269.4.C1057"},{"key":"12","unstructured":"12) Anderson JM, Glade JL, Stevenson BR, Boyer JL, Mooseker MS. Hepatic immunohistochemical localization of the tight junction protein ZO-1 in rat models of cholestasis. Am. J. Pathol.<\/i>, 134<\/b>, 1055\u20131062 (1989)."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Pijls KE, Jonkers DMAE, Elamin EE, Masclee AAM, Koek GH. Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature. Liver Int.<\/i>, 33<\/b>, 1457\u20131469 (2013).","DOI":"10.1111\/liv.12271"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Khailova L, Dvorak K, Arganbright KM, Williams CS, Halpern MD, Dvorak B. Changes in hepatic cell junctions structure during experimental necrotizing enterocolitis: effect of EGF treatment. Pediatr. Res.<\/i>, 66<\/b>, 140\u2013144 (2009).","DOI":"10.1203\/PDR.0b013e3181aa3198"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Lora L, Mazzon E, Martines D, Fries W, Muraca M, Martin A, d\u2019Odorico A, Naccarato R, Citi S. Hepatocyte tight-junctional permeability is increased in rat experimental colitis. Gastroenterology<\/i>, 113<\/b>, 1347\u20131354 (1997).","DOI":"10.1053\/gast.1997.v113.pm9322530"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Kawaguchi T, Sakisaka S, Mitsuyama K, Harada M, Koga H, Taniguchi E, Sasatomi K, Kimura R, Ueno T, Sawada N, Mori M, Sata M. Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis. Hepatology<\/i>, 31<\/b>, 1285\u20131295 (2000).","DOI":"10.1053\/jhep.2000.7435"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Al-Sadi R, Guo S, Ye D, Rawat M, Ma TY. TNF-\u03b1 modulation of intestinal tight junction permeability is mediated by NIK\/IKK-\u03b1 axis activation of the canonical NF-\u03baB pathway. Am. J. Pathol.<\/i>, 186<\/b>, 1151\u20131165 (2016).","DOI":"10.1016\/j.ajpath.2015.12.016"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Ma TY, Iwamoto GK, Hoa NT, Akotia V, Pedram A, Boivin MA, Said HM. TNF-\u03b1-induced increase in intestinal epithelial tight junction permeability requires NF-\u03baB activation. Am. J. Physiol. Gastrointest. Liver Physiol.<\/i>, 286<\/b>, G367\u2013G376 (2004).","DOI":"10.1152\/ajpgi.00173.2003"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Adams RB, Planchon SM, Roche JK. IFN-gamma modulation of epithelial barrier function. Time course, reversibility, and site of cytokine binding. J. Immunol.<\/i>, 150<\/b>, 2356\u20132363 (1993).","DOI":"10.4049\/jimmunol.150.6.2356"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Mazzon E, Puzzolo D, Caputi AP, Cuzzocrea S. Role of IL-10 in hepatocyte tight junction alteration in mouse model of experimental colitis. Mol. Med.<\/i>, 8<\/b>, 353\u2013366 (2002).","DOI":"10.1007\/BF03402016"},{"key":"21","unstructured":"21) Mazzon E, Cuzzocrea S. Role of iNOS in hepatocyte tight junction alteration in mouse model of experimental colitis. Cell. Mol. Biol.<\/i>, 49<\/b>, 45\u201357 (2003)."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology<\/i>, 96<\/b>, 795\u2013803 (1989).","DOI":"10.1016\/0016-5085(89)90904-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Wang J, Zhang Z, Fang A, Wu K, Chen X, Wang G, Mao F. Resveratrol attenuates inflammatory bowel disease in mice by regulating SUMO1. Biol. Pharm. Bull.<\/i>, 43<\/b>, 450\u2013457 (2020).","DOI":"10.1248\/bpb.b19-00786"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Sann H, von Erichsen J, Hessmann M, Pahl A, Hoffmeyer A. Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice. Life Sci.<\/i>, 92<\/b>, 708\u2013718 (2013).","DOI":"10.1016\/j.lfs.2013.01.028"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Zhang F, Xi L, Duan Y, Qin H, Wei M, Wu Y, Li B, Zhou Y, Wu X. The ileum-liver farnesoid X receptor signaling axis mediates the compensatory mechanism of 17\u03b1-ethynylestradiol-induced cholestasis via<\/i> increasing hepatic biosynthesis of chenodeoxycholic acids in rats. Eur. J. Pharm. Sci.<\/i>, 123<\/b>, 404\u2013415 (2018).","DOI":"10.1016\/j.ejps.2018.08.005"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Shibuya T, Takei Y, Hirose M, Ikejima K, Enomoto N, Maruyama A, Sato N. A double-strand decoy DNA oligomer for NF-kappaB inhibits TNFalpha-induced ICAM-1 expression in sinusoidal endothelial cells. Biochem. Biophys. Res. Commun.<\/i>, 298<\/b>, 10\u201316 (2002).","DOI":"10.1016\/S0006-291X(02)02369-0"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Lamb K, Zhong F, Gebhart GF, Bielefeldt K. Experimental colitis in mice and sensitization of converging visceral and somatic afferent pathways. Am. J. Physiol. Gastrointest. Liver Physiol.<\/i>, 290<\/b>, G451\u2013G457 (2006).","DOI":"10.1152\/ajpgi.00353.2005"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Silva I, Pinto R, Mateus V. Preclinical study in vivo<\/i> for new pharmacological approaches in inflammatory bowel disease: a systematic review of chronic model of TNBS-induced colitis. J. Clin. Med.<\/i>, 8<\/b>, 1574 (2019).","DOI":"10.3390\/jcm8101574"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Kawaguchi T, Sakisaka S, Mitsuyama K, Harada M, Koga H, Taniguchi E, Sasatomi K, Kimura R, Ueno T, Sawada N, Mori M, Sata M. Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis. Hepatology<\/i>, 31<\/b>, 1285\u20131295 (2000).","DOI":"10.1053\/jhep.2000.7435"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Lora L, Mazzon E, Martines D, Fries W, Muraca M, Martin A, d\u2019Odorico A, Naccarato R, Citi S. Hepatocyte tight-junctional permeability is increased in rat experimental colitis. Gastroenterology<\/i>, 113<\/b>, 1347\u20131354 (1997).","DOI":"10.1053\/gast.1997.v113.pm9322530"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood<\/i>, 119<\/b>, 651\u2013665 (2012).","DOI":"10.1182\/blood-2011-04-325225"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Muth KN, Rech J, Losch FO, Hoerning A. Reversing the inflammatory process-25 years of tumor necrosis factor-\u03b1 inhibitors. J. Clin. Med.<\/i>, 12<\/b>, 5039 (2023).","DOI":"10.3390\/jcm12155039"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) van Hogezand RA, Verspaget HW. The future role of anti-tumour necrosis factor-alpha products in the treatment of Crohn\u2019s disease. Drugs<\/i>, 56<\/b>, 299\u2013305 (1998).","DOI":"10.2165\/00003495-199856030-00001"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu. Rev. Med.<\/i>, 51<\/b>, 289\u2013298 (2000).","DOI":"10.1146\/annurev.med.51.1.289"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Neurath MF. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol.<\/i>, 14<\/b>, 329\u2013342 (2014).","DOI":"10.1038\/nri3661"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Murakami Y, Fujiya M, Konishi MH, Isozaki S, Sugiyama Y, Kobayashi Y, Sasaki T, Kunogi T, Takahashi K, Ando K, Ueno N, Kashima S, Moriichi K, Tanabe H, Okumura T. The optimal dose of tacrolimus in combination therapy with an anti-TNF\u03b1 antibody in a mouse colitis model. Biol. Pharm. Bull.<\/i>, 44<\/b>, 564\u2013570 (2021).","DOI":"10.1248\/bpb.b20-00916"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Burr NE, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut<\/i>, 2021<\/b>, 326390 (2021).","DOI":"10.1136\/gutjnl-2021-326390"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Fischer A, Gluth M, Pape U-F, Wiedenmann B, Theuring F, Baumgart DC. Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-\u03b1 on tight junction proteins and signaling pathways in intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol.<\/i>, 304<\/b>, G970\u2013G979 (2013).","DOI":"10.1152\/ajpgi.00183.2012"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Le N, Mazahery C, Nguyen K, Levine AD. Regulation of intestinal epithelial barrier and immune function by activated t cells. Cell. Mol. Gastroenterol. Hepatol.<\/i>, 11<\/b>, 55\u201376 (2021).","DOI":"10.1016\/j.jcmgh.2020.07.004"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Zihni C, Mills C, Matter K, Balda MS. Tight junctions: from simple barriers to multifunctional molecular gates. Nat. Rev. Mol. Cell Biol.<\/i>, 17<\/b>, 564\u2013580 (2016).","DOI":"10.1038\/nrm.2016.80"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Erickson N, Mohanty SK, Shivakumar P, Sabla G, Chakraborty R, Bezerra JA. Temporal-spatial activation of apoptosis and epithelial injury in murine experimental biliary atresia. Hepatology<\/i>, 47<\/b>, 1567\u20131577 (2008).","DOI":"10.1002\/hep.22229"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Xu J, Kausalya PJ, Van Hul N, Caldez MJ, Xu S, Ong AGM, Woo WL, Mohamed Ali S, Kaldis P, Hunziker W. Protective functions of ZO-2\/Tjp2 expressed in hepatocytes and cholangiocytes against liver injury and cholestasis. Gastroenterology<\/i>, 160<\/b>, 2103\u20132118 (2021).","DOI":"10.1053\/j.gastro.2021.01.027"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Zhao R, Wu X, Bi X-Y, Yang H, Zhang Q. Baicalin attenuates blood\u2013spinal cord barrier disruption and apoptosis through PI3K\/Akt signaling pathway after spinal cord injury. Neural Regen. Res.<\/i>, 17<\/b>, 1080\u20131087 (2022).","DOI":"10.4103\/1673-5374.324857"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) He S, Guo Y, Zhao J, Xu X, Wang N, Liu Q. Ferulic acid ameliorates lipopolysaccharide-induced barrier dysfunction via<\/i> MicroRNA-200c-3p-mediated activation of PI3K\/AKT pathway in Caco-2 cells. Front. Pharmacol.<\/i>, 11<\/b>, 376 (2020).","DOI":"10.3389\/fphar.2020.00376"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Zou P, Yang F, Ding Y, Zhang D, Liu Y, Zhang J, Wu D, Wang Y. Lipopolysaccharide downregulates the expression of ZO-1 protein through the Akt pathway. BMC Infect. Dis.<\/i>, 22<\/b>, 774 (2022).","DOI":"10.1186\/s12879-022-07752-1"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Manthari RK, Tikka C, Ommati MM, Niu R, Sun Z, Wang J, Zhang J, Wang J. Arsenic induces autophagy in developmental mouse cerebral cortex and hippocampus by inhibiting PI3K\/Akt\/mTOR signaling pathway: involvement of blood\u2013brain barrier\u2019s tight junction proteins. Arch. Toxicol.<\/i>, 92<\/b>, 3255\u20133275 (2018).","DOI":"10.1007\/s00204-018-2304-y"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Liu Y, Tie L. Apolipoprotein M and sphingosine-1-phosphate complex alleviates TNF-\u03b1-induced endothelial cell injury and inflammation through PI3K\/AKT signaling pathway. BMC Cardiovasc. Disord.<\/i>, 19<\/b>, 279 (2019).","DOI":"10.1186\/s12872-019-1263-4"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Xu C, Feng C, Huang P, Li Y, Liu R, Liu C, Han Y, Chen L, Ding Y, Shao C, Shi Y. TNF\u03b1 and IFN\u03b3 rapidly activate PI3K-AKT signaling to drive glycolysis that confers mesenchymal stem cells enhanced anti-inflammatory property. Stem Cell Res. Ther.<\/i>, 13<\/b>, 491 (2022).","DOI":"10.1186\/s13287-022-03178-3"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Mazzon E, Puzzolo D, Caputi AP, Cuzzocrea S. Role of IL-10 in hepatocyte tight junction alteration in mouse model of experimental colitis. Mol. Med.<\/i>, 8<\/b>, 353\u2013366 (2002).","DOI":"10.1007\/BF03402016"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/46\/12\/46_b23-00503\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:53:23Z","timestamp":1715576003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/46\/12\/46_b23-00503\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b23-00503","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"article-number":"b23-00503"}}